Maximum quantity allowed is 999
请选择数量
CAS RN: 162401-32-3 | 產品號碼: R0193
Roflumilast
×
![]()
×
| 包裝 | 價格 | 同一天 | 2-3个工作日 |
|---|---|---|---|
| 250MG |
NT$2,080
|
2 | 18 |
| 1G |
NT$6,200
|
27 | 聯繫我們 |
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | R0193 |
| 純度/分析方法 | >98.0%(HPLC) |
| 分子式 / 分子量 | C__1__7H__1__4Cl__2F__2N__2O__3 = 403.21 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Frozen (-20°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片）, 250MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 162401-32-3 |
| Reaxys-RN | 9802592 |
| PubChem Substance ID | 354334855 |
| Merck Index(14) | 8249 |
| MDL編號 | MFCD00938270 |
產品規格
| Appearance | White to Orange to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 97.0 % |
| Melting point | 157.0 to 161.0 °C |
性質
| 熔點 | 159 °C |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| 防範說明 | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
相關法規
| RTECS # | CV3325600 |
運輸資料
| HS編碼* | 2933.39-000 |
Application
Roflumilast: A Selective Phosphodiesterase 4 (PDE4) Inhibitor.
Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor. The active metabolite, Roflumilast N-oxide [R0217], also acts as a selective PDE4 inhibitor. PDE4 is a key enzyme in the degradation of cyclic adenosine monophosphate (cyclic AMP) [A2381] and is centrally involved in the cytokine production of inflammatory cells. The inhibition of PDE4 activity leads to accumulation of intracellular cyclic AMP. Roflumilast is used for the treatment of chronic obstructive pulmonary disease (COPD). While the precise mechanism of the therapeutic action in COPD is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in lung cells. For your reference, [C3395] and [D4505] are synthetic intermediates of roflumilast. (The product is for research purpose only.)
References
- Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
- Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease (a review)
- The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease (a review)
- Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation
- Isolation, synthesis and structure confirmation of the impurity in crude roflumilast product
考研文獻
TCIMail
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。